Magnesium treatment for neuroprotection in ischemic diseases of the brain

Experimental and Translational Stroke Medicine

Volumn 5, Issue 1, 2013, Pages

  Westermaier, Thomas ^a   Stetter, Christian ^a   Kunze, Ekkehard ^a   Willner, Nadine ^a   Raslan, Furat ^a   Vince, Giles H ^b   Ernestus, Ralf Ingo ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; NIMODIPINE; PLACEBO;

BRADYCARDIA; BRAIN ARTERY ANEURYSM RUPTURE; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DIARRHEA; HUMAN; HYPOCALCEMIA; HYPOTENSION; NEUROPROTECTION; OUTCOME ASSESSMENT; PERINATAL ASPHYXIA; PREMATURE LABOR; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SUBARACHNOID HEMORRHAGE;

EID: 84876960667     PISSN: None     EISSN: 20407378     Source Type: Journal    
DOI: 10.1186/2040-7378-5-6     Document Type: Review

References (80)

1. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Part I: Pathophysiology. J Neurosurg 1992, 77(2):169-184.
2. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008, 55(3):363-389. 10.1016/j.neuropharm.2007.12.007, 2631228, 18308347.
3. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J 1984, 108(1):188-193. 10.1016/0002-8703(84)90572-6, 6375330.
4. Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio A. Mg2+-Ca2+ interaction in contractility of vascular smooth muscle: Mg2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol 1987, 65(4):729-745. 10.1139/y87-120, 3300911.
5. Dong JF, Cruz MA, Aboulfatova K, Martin C, Choi H, Bergeron AL, Martini SR, Kroll MH, Kent TA. Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost 2000, 99(3):586-593.
6. Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R. Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens 2000, 18(7):919-926. 10.1097/00004872-200018070-00014, 10930190.
7. Schauf B, Becker S, Abele H, Klever T, Wallwiener D, Aydeniz B. Effect of magnesium on red blood cell deformability in pregnancy. Hypertens Pregnancy 2004, 24(1):17-27.
8. Peruche B, Krieglstein J. Mechanisms of drug actions against neuronal damage caused by ischemia-an overview. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17(1):21-70. 10.1016/0278-5846(93)90032-N, 8416602.
9. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 1984, 307(5950):462-465. 10.1038/307462a0, 6320006.
10. Kristal BS, Dubinsky JM. Mitochondrial permeability transition in the central nervous system: induction by calcium cycling-dependent and -independent pathways. J Neurochem 1997, 69(2):524-538.
11. Schanne FA, Gupta RK, Stanton PK. 31P-NMR study of transient ischemia in rat hippocampal slices in vitro. Biochim Biophys Acta 1993, 1158(3):257-263. 10.1016/0304-4165(93)90023-2, 8251525.
12. Mohr K. Therapeutic drugs. Magnesium. Dtsch Med Wochenschr 1994, 119(48):1669-1670.
13. Westermaier T, Zausinger S, Baethmann A, Schmid-Elsaesser R. Dose finding study of intravenous magnesium sulphate in transient focal cerebral ischemia in rats. Acta Neurochir (Wien) 2005, 147(5):525-532.
14. Boet R, Mee E. Magnesium sulfate in the management of patients with Fisher Grade 3 subarachnoid hemorrhage: a pilot study. Neurosurgery 2000, 47(3):602-606.
15. Chia RY, Hughes RS, Morgan MK. Magnesium: a useful adjunct in the prevention of cerebral vasospasm following aneurysmal subarachnoid haemorrhage. J Clin Neurosci 2002, 9(3):279-281. 10.1054/jocn.2001.1039, 12093134.
16. Muir KW, Lees KR. Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke 1998, 29(5):918-923. 10.1161/01.STR.29.5.918, 9596235.
17. van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, Rinkel GJ. Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial. Stroke 2005, 36(5):1011-1015. 10.1161/01.STR.0000160801.96998.57, 15790946.
18. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, Marrocco A, Thomas AJ, Mitsias PD, Malik GM. Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage. J Neurosurg 2002, 96(3):510-514. 10.3171/jns.2002.96.3.0510, 11883835.
19. Westermaier T, Stetter C, Vince GH, Pham M, Tejon JP, Eriskat J, Kunze E, Matthies C, Ernestus RI, Solymosi L, Roosen K. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, clinical study. Crit Care Med 2010, 38(5):1284-1290.
20. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke 2010, 41(5):921-926. 10.1161/STROKEAHA.109.571125, 20378868.
21. Muroi C, Terzic A, Fortunati M, Yonekawa Y, Keller E. Magnesium sulfate in the management of patients with aneurysmal subarachnoid hemorrhage: a randomized, placebo-controlled, dose-adapted trial. Surg Neurol 2008, 69(1):33-39. 10.1016/j.surneu.2007.07.015, 18054611.
22. Blair JL, Warner DS, Todd MM. Effects of elevated plasma magnesium versus calcium on cerebral ischemic injury in rats. Stroke 1989, 20(4):507-512. 10.1161/01.STR.20.4.507, 2648653.
23. Sirin BH, Coskun E, Yilik L, Ortac R, Sirin H, Tetik C. Neuroprotective effects of preischemia subcutaneous magnesium sulfate in transient cerebral ischemia. Eur J Cardiothorac Surg 1998, 14(1):82-88. 10.1016/S1010-7940(98)00140-7, 9726620.
24. Zhou H, Ma Y, Zhou Y, Liu Z, Wang K, Chen G. Effects of magnesium sulfate on neuron apoptosis and expression of caspase-3, bax and bcl-2 after cerebral ischemia-reperfusion injury. Chin Med J (Engl) 2003, 116(10):1532-1534.
25. Zhu H, Meloni BP, Bojarski C, Knuckey MW, Knuckey NW. Post-ischemic modest hypothermia (35 degrees C) combined with intravenous magnesium is more effective at reducing CA1 neuronal death than either treatment used alone following global cerebral ischemia in rats. Exp Neurol 2005, 193(2):361-368. 10.1016/j.expneurol.2005.01.022, 15869938.
26. Zhu H, Meloni BP, Moore SR, Majda BT, Knuckey NW. Intravenous administration of magnesium is only neuroprotective following transient global ischemia when present with post-ischemic mild hypothermia. Brain Res 2004, 1014(1-2):53-60.
27. Chung SY, Lin JY, Lin MC, Liu HM, Wang MF, Cheng FC. Synergistic efficacy of magnesium sulfate and FK506 on cerebral ischemia-induced infarct volume in gerbil. Med Sci Monit 2004, 10(4):BR105-BR108.
28. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1991, 11(6):1025-1030. 10.1038/jcbfm.1991.170, 1939380.
29. Lee EJ, Ayoub IA, Harris FB, Hassan M, Ogilvy CS, Maynard KI. Mexiletine and magnesium independently, but not combined, protect against permanent focal cerebral ischemia in Wistar rats. J Neurosci Res 1999, 58(3):442-448. 10.1002/(SICI)1097-4547(19991101)58:3<442::AID-JNR10>3.0.CO;2-4, 10518118.
30. Roffe C, Thomas L, Fotheringham A, Davies I. The effect of megnesium on infarct size and oedema after middle cerebral artery occlusion in rats. Cerebrovasc Dis 1996, 6(Suppl. 2):42.
31. Yang Y, Li Q, Ahmad F, Shuaib A. Survival and histological evaluation of therapeutic window of post-ischemia treatment with magnesium sulfate in embolic stroke model of rat. Neurosci Lett 2000, 285(2):119-122. 10.1016/S0304-3940(00)01048-X, 10793241.
32. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE. Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996, 85(1):117-124. 10.3171/jns.1996.85.1.0117, 8683260.
33. Westermaier T, Hungerhuber E, Zausinger S, Baethmann A, Schmid-Elsaesser R. Neuroprotective efficacy of intra-arterial and intravenous magnesium sulfate in a rat model of transient focal cerebral ischemia. Acta Neurochir (Wien) 2003, 145(5):393-399.
34. Schmid-Elsaesser R, Zausinger S, Hungerhuber E, Baethmann A, Reulen HJ. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurgery 1999, 44(1):163-171. 10.1097/00006123-199901000-00100, 9894977.
35. Spandou E, Soubasi V, Papoutsopoulou S, Augoustides-Savvopoulou P, Loizidis T, Pazaiti A, Karkavelas G, Guiba-Tziampiri O. Neuroprotective effect of long-term MgSO4 administration after cerebral hypoxia-ischemia in newborn rats is related to the severity of brain damage. Reprod Sci 2007, 14(7):667-677. 10.1177/1933719107305864, 18000228.
36. Thordstein M, Bagenholm R, Thiringer K, Kjellmer I. Scavengers of free oxygen radicals in combination with magnesium ameliorate perinatal hypoxic-ischemic brain damage in the rat. Pediatr Res 1993, 34(1):23-26. 10.1203/00006450-199307000-00006, 8356013.
37. Greenwood K, Cox P, Mehmet H, Penrice J, Amess PN, Cady EB, Wyatt JS, Edwards AD. Magnesium sulfate treatment after transient hypoxia-ischemia in the newborn piglet does not protect against cerebral damage. Pediatr Res 2000, 48(3):346-350. 10.1203/00006450-200009000-00014, 10960501.
38. Penrice J, Amess PN, Punwani S, Wylezinska M, Tyszczuk L, D'Souza P, Edwards AD, Cady EB, Wyatt JS, Reynolds EO. Magnesium sulfate after transient hypoxia-ischemia fails to prevent delayed cerebral energy failure in the newborn piglet. Pediatr Res 1997, 41(3):443-447. 10.1203/00006450-199703000-00024, 9078550.
39. Hoffman DJ, Marro PJ, McGowan JE, Mishra OP, Delivoria-Papadopoulos M. Protective effect of MgSO4 infusion on nmda receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet. Brain Res 1994, 644(1):144-149. 10.1016/0006-8993(94)90357-3, 8032941.
40. Wester PO, Asplund K, Eriksson S, Hagg E, Lithner F, Strand T. Infusion of magnesium in patients with acute brain infarction. Acta Neurol Scand 1984, 70(2):143.
41. Muir KW, Lees KR. A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke 1995, 26(7):1183-1188. 10.1161/01.STR.26.7.1183, 7541572.
42. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992, 339(8809):1553-1558. 10.1016/0140-6736(92)91828-V, 1351547.
43. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet 2004, 363(9407):439-445.
44. Aslanyan S, Weir CJ, Muir KW, Lees KR. Magnesium for treatment of acute lacunar stroke syndromes: further analysis of the IMAGES trial. Stroke 2007, 38(4):1269-1273. 10.1161/01.STR.0000259628.94421.09, 17347471.
45. Saver JL, Kidwell C, Eckstein M, Starkman S. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke 2004, 35(5):106-108.
46. Bederson JB, Germano IM, Guarino L. Cortical blood flow and cerebral perfusion pressure in a new noncraniotomy model of subarachnoid hemorrhage in the rat. Stroke 1995, 26(6):1086-1091. 10.1161/01.STR.26.6.1086, 7762027.
47. Westermaier T, Jauss A, Vince GH, Raslan F, Eriskat J, Roosen K. Impact of various extents of experimental subarachnoid hemorrhage induced by the endovascular filament model on mortality and changes of cerebral blood flow. J Exp Stroke Transl Med 2011, 4(1):8-15.
48. Jones TH, Morawetz RB, Crowell RM, Marcoux FW, FitzGibbon SJ, DeGirolami U, Ojemann RG. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981, 54(6):773-782. 10.3171/jns.1981.54.6.0773, 7241187.
49. van den Bergh WM, Algra A, van der Sprenkel JW, Tulleken CA, Rinkel GJ. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003, 52(2):276-281. 10.1227/01.NEU.0000043984.42487.0E, 12535355.
50. Luo W, Qiu S, Ma W. Clinical study of magnesium sulphate on delayed cerebral vasospasmafter subarachnoid haemorrhage. Journal of Clinical Neurology 1996, 9(4):244-245.
51. Schmid-Elsaesser R, Kunz M, Zausinger S, Prueckner S, Briegel J, Steiger HJ. Intravenous magnesium versus nimodipine in the treatment of patients with aneurysmal subarachnoid hemorrhage: a randomized study. Neurosurgery 2006, 58(6):1054-1065. 10.1227/01.NEU.0000215868.40441.D9, 16723884.
52. Mees SM, Algra A, Vandertop WP, van Kooten F, Kuijsten HA, Boiten J, van Oostenbrugge RJ, Salman RA, Lavados PM, Rinkel GJ, van den Bergh WM. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012, 380(9836):44-9. 10.1016/S0140-6736(12)60724-7, 3391717, 22633825.
53. Prevedello DM, Cordeiro JG, de Morais AL, Saucedo NSJ, Chen IB, Araujo JC. Magnesium sulfate: role as possible attenuating factor in vasospasm morbidity. Surg Neurol 2006, 65(Suppl 1):14-20.
54. Stippler M, Crago E, Levy EI, Kerr ME, Yonas H, Horowitz MB, Kassam A. Magnesium infusion for vasospasm prophylaxis after subarachnoid hemorrhage. J Neurosurg 2006, 105(5):723-729. 10.3171/jns.2006.105.5.723, 17121134.
55. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989, 298(6674):636-642. 10.1136/bmj.298.6674.636, 1835889, 2496789.
56. Dorhout MS, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007, 3. CD000277.
57. Pritchard JA. The use of the magnesium ion in the management of eclamptogenic toxemias. Surg Gynecol Obstet 1955, 100(2):131-140.
58. Belfort MA, Anthony J, Saade GR, Allen JCJ. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. N Engl J Med 2003, 348(4):304-311. 10.1056/NEJMoa021180, 12540643.
59. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995, 333(4):201-205. 10.1056/NEJM199507273330401, 7791836.
60. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants?. Pediatrics 1995, 95(2):263-269.
61. Schendel DE, Berg CJ, Yeargin-Allsopp M, Boyle CA, Decoufle P. Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996, 276(22):1805-1810. 10.1001/jama.1996.03540220029026, 8946900.
62. Blair E, Palmer L, Stanley F. Cerebral palsy in very low birth weight infants, pre-eclampsia and magnesium sulphate. Pediatrics 1996, 97(5):780-782.
63. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Leveque C, Hellot MF, Benichou J. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG 2007, 114(3):310-318.
64. Crowther CA, Hiller JE, Doyle LW, Haslam RR. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003, 290(20):2669-2676. 10.1001/jama.290.20.2669, 14645308.
65. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JMJ, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O'Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008, 359(9):895-905. 10.1056/NEJMoa0801187, 2803083, 18753646.
66. Magpie Trial Follow-Up Collaborative Group The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months. BJOG 2007, 114(3):289-299. 2063969, 17166221, Magpie Trial Follow-Up Collaborative Group.
67. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2009, 1. CD004661.
68. Levene M, Blennow M, Whitelaw A, Hanko E, Fellman V, Hartley R. Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. Arch Dis Child Fetal Neonatal Ed 1995, 73(3):174-177.
69. Groenendaal F, Rademaker CM, Toet MC, de Vries LS. Effects of magnesium sulphate on amplitude-integrated continuous EEG in asphyxiated term neonates. Acta Paediatr 2002, 91(10):1073-1077. 10.1111/j.1651-2227.2002.tb00102.x, 12434893.
70. Ichiba H, Tamai H, Negishi H, Ueda T, Kim TJ, Sumida Y, Takahashi Y, Fujinaga H, Minami H. Randomized controlled trial of magnesium sulfate infusion for severe birth asphyxia. Pediatr Int 2002, 44(5):505-509. 10.1046/j.1442-200X.2002.01610.x, 12225549.
71. Gathwala G, Khera A, Singh I. Magnesium therapy in birth asphyxia. Indian J Pediatr 2006, 73(3):209-212. 10.1007/BF02825482, 16567913.
72. Bhat MA, Charoo BA, Bhat JI, Ahmad SM, Ali SW, Mufti MU. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial. Pediatrics 2009, 123(5):e764-e769. 10.1542/peds.2007-3642, 19349375.
73. Gathwala G, Khera A, Singh J, Balhara B. Magnesium for neuroprotection in birth asphyxia. J Pediatr Neurosci 2010, 5(2):102-104. 10.4103/1817-1745.76094, 3087983, 21559152.
74. Zausinger S, Westermaier T, Plesnila N, Steiger HJ, Schmid-Elsaesser R. Neuroprotection in transient focal cerebral ischemia by combination drug therapy and mild hypothermia: comparison with customary therapeutic regimen. Stroke 2003, 34(6):1526-1532. 10.1161/01.STR.0000070841.31224.29, 12730554.
75. Zausinger S, Scholler K, Plesnila N, Schmid-Elsaesser R. Combination drug therapy and mild hypothermia after transient focal cerebral ischemia in rats. Stroke 2003, 34(9):2246-2251. 10.1161/01.STR.0000083622.65684.21, 12893947.
76. Kimura T, Yasue H, Sakaino N, Rokutanda M, Jougasaki M, Araki H. Effects of magnesium on the tone of isolated human coronary arteries. Comparison with diltiazem and nitroglycerin. Circulation 1989, 79(5):1118-1124. 10.1161/01.CIR.79.5.1118, 2496936.
77. Pyne GJ, Cadoux-Hudson TA, Clark JF. Magnesium protection against in vitro cerebral vasospasm after subarachnoid haemorrhage. Br J Neurosurg 2001, 15(5):409-415. 10.1080/02688690120082413, 11708544.
78. Mori K, Miyazaki M, Iwata J, Yamamoto T, Nakao Y. Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat. Neurosurg Rev 2008, 31(2):197-203. 10.1007/s10143-008-0122-z, 18253770.
79. Mori K, Yamamoto T, Nakao Y, Miyazaki M, Iwata J, Tamura M, Shiroishi T. Novel neuroprotective effect of cisternal and intra-cerebral magnesium sulfate solution infusion on delayed cerebral death in rat hippocampal neurons after transient global ischemia. Brain Res 2012, 22(1480):72-80.
80. Mori K, Yamamoto T, Nakao Y, Osada H, Hara Y, Oyama K, Esaki T. Initial clinical experience of vasodilatory effect of intra-cisternal infusion of magnesium sulfate for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurol Med Chir 2009, 49(4):139-144.